European Commission approves Novartis anti-inflammatory drug Cosentyx (good, secukinumab) label update
-
Last Update: 2020-06-07
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
, SwissPharmaceuticals(http://giant Novartis announced that the European Commission (EC) has approved an update to the label of the anti-inflammatory drug Cosentyx (secukinumab)The label update is based on data from the MEASURE 3 study, a three-year study that explores cosentyx's tolerance and efficacy in AS patientsthe response rate was higher in the 300mg dose group than the recommended 150mg dose, especially in patients who had previously been treated with anti-TNF preparationsThe safety in this study is consistent with previous studiesAbout Cosentyx
Cosentyx is the first and one-specific target inhibition of leukin-17A (IL-17A) of all-human monoclonal antibodies
drug(http://that selectively targets the activity of circulating IL-17A, reduces immune system activity and improves disease symptomsstudies have revealed that IL-17A plays an important role in driving the body's immune response to a variety of autoimmune diseases, including psoriasis arthritis (PsA), plaque psoriasis (PsO), and strong scoliosis (AS)Cosentyx was approved for the market in January 2015 and has now been approved for three indications (PsO, PsA, AS)Cosentyx has five years of continuous efficacy and safety data on three major indications, with more than 250,000 patients treated worldwideIn China, Cosentyx (®) was approved on April 1, 2019 to treat adult patients with moderate to severe plaque psoriasis that meets the signs of systemic therapy or phototherapy
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
